Physician profile
Mohan P Abraham
NPI 1740299965
$9,839.22
in general payments reported to CMS, 2019-2025
23 companies · $24.06 in 2025
The $24.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,101 · 2020: $1,951 · 2021: $2,170 · 2022: $2,448 · 2023: $1,145 · 2025: $24.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,944.67 | 2019-2023 | Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,474.47 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,047.91 | 2019-2022 | |
| Glaxosmithkline, LLC. | $990.33 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $605.93 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $569.36 | 2019-2022 | |
| Abbvie INC. | $414.04 | 2021-2023 | Qulipta, Ubrelvy |
| Amarin Pharma, INC. | $397.45 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $374.77 | 2022-2023 | Dupixent |
| Pfizer INC. | $343.81 | 2019-2022 | |
| Lilly USA, LLC | $340.66 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $316.75 | 2019-2020 | |
| Daiichi Sankyo INC. | $226.68 | 2019-2023 | Injectafer |
| Genzyme Corporation | $208.75 | 2021-2022 | |
| Esperion Therapeutics, INC. | $129.92 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $121.34 | 2021 | |
| Novartis Pharmaceuticals Corporation | $93.97 | 2019-2022 | |
| Indivior INC. | $66.60 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $64.89 | 2019-2022 | |
| Philips North America LLC | $38.93 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $24.07 | 2023 | Kristalose |
| Otsuka America Pharmaceutical, INC. | $24.06 | 2025 | Jynarque |
| Renalytix Ai, INC. | $19.86 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.